COMPANY RESEARCHAbsci Corporation
Absci is a biotechnology company that combines artificial intelligence with experimental biology to discover and design therapeutic antibodies. Its approach links computational protein design to laboratory testing, with the goal of creating antibody candidates that can be investigated in drug development. Absci pursues internal therapeutic research and also works with pharmaceutical collaborators on selected programs. The company is distinct from a software-only or contract-service provider because its activities include the development of investigational therapeutic molecules. The official corporate and investor relations websites provide the appropriate sources for updated information about specific research programs, collaborations and securities disclosures.
Company at a glance
Corporate information
- Company entity
- Absci Corporation
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.absci.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Global Select Market: ABSI
generative AI · antibody engineering
immunology · oncology · therapeutic antibodies
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Absci is a biotechnology company that combines artificial intelligence with experimental biology to discover and design therapeutic antibodies. Its approach links computational protein design to laboratory testing, with the goal of creating antibody candidates that can be investigated in drug development. Absci pursues internal therapeutic research and also works with pharmaceutical collaborators on selected programs. The company is distinct from a software-only or contract-service provider because its activities include the development of investigational therapeutic molecules. The official corporate and investor relations websites provide the appropriate sources for updated information about specific research programs, collaborations and securities disclosures.
Business, technology & evidence
- SecuritiesNasdaq Global Select Market: ABSI
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Absci Corporation ↗Absci Corporation ·
- Official issuer and R&D disclosure · Absci Corporation ↗Absci Corporation ·
- Official issuer and R&D disclosure · Absci Corporation ↗Absci Corporation ·
- Official issuer and R&D disclosure · Absci Corporation ↗Absci Corporation ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.